The company said, “The Company is increasing full-year 2025 Adjusted EBITDA guidance to $115.0 – 120.0 million and projected full-year 2025 Modern Oral sales to $125.0 – 130.0 million.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TPB: